Dave Shruti D, Trivedi Hargovind L, Chooramani Saroj G, Chandra Tulika
Department of Pathology, G R Doshi and K M Mehta Institute of Kidney Diseases and Research Centre (IKDRC)-Dr HL Trivedi Institute of Transplantation Sciences (ITS), Ahmedabad, Gujarat, India.
BMJ Case Rep. 2013 Jul 26;2013:bcr2013200226. doi: 10.1136/bcr-2013-200226.
Type 1 diabetes mellitus (T1DM) is a result of autoimmune destruction of insulin-producing β cells of pancreas. Insulin is a widely used therapeutic modality. Nearing a complete century since the discovery of insulin, it is time to expect change in management strategies of T1DM. We report two men aged 22 and 15 years, respectively, with T1DM since 6 and 11 years, on exogenous insulin therapy of 64 and 56 International units (IU)/day respectively. We infused in vitro generated insulin-making cells trans-differentiated from donor adipose tissue derived mesenchymal stem cells and bone marrow-derived haematopoietic stem cells in their abdominal subcutaneous tissue, portal and thymic circulation under non-myeloablative conditioning. Over follow-up of 22.93 and 13.8 months they have stable blood sugar levels with glycosylated haemoglobin level of 6.3% and 6.8% with present insulin requirement of 18 and 22 IU/day, respectively.
1型糖尿病（T1DM）是胰腺中产生胰岛素的β细胞发生自身免疫性破坏的结果。胰岛素是一种广泛使用的治疗方式。自胰岛素被发现至今已近一个世纪，是时候期待1型糖尿病管理策略的改变了。我们报告了两名分别为22岁和15岁的男性，他们分别患T1DM 6年和11年，分别接受64和56国际单位（IU）/天的外源性胰岛素治疗。我们在非清髓性预处理条件下，将从供体脂肪组织来源的间充质干细胞和骨髓来源的造血干细胞经转分化体外生成的胰岛素生成细胞注入他们的腹部皮下组织、门静脉和胸腺循环。在22.93个月和13.8个月的随访中，他们的血糖水平稳定，糖化血红蛋白水平分别为6.3%和6.8%，目前胰岛素需求量分别为18 IU/天和22 IU/天。
